TECTONIC THERAPEUTIC INC

CEO’s 7,500‑share performance‑option deal shows confidence in Tectonic’s upcoming Phase‑2 trial, hinting at future upside for shareholders.

CEO’s bulk RSU purchase shows Tectonic Therapeutic insiders trust the gene‑therapy pipeline, boosting investor confidence and potential upside.

CEO insider buy at $21.10 shows confidence in Tectonic Therapeutics’ single‑dose gene therapy pipeline and signals potential upside for investors.

CEO Reicin Alise’s recent buy of 2,500 Tectonic Therapeutic shares at $21.10—below market and 52‑week lows—signals insider confidence in the company’s gene‑therapy pipeline, offering investors insight into strategic repositioning amid market volatil…

Lochner Daniel’s $21.61 buy of 6,000 shares shows quiet confidence in Tectonic’s pipeline—insider buying paired with rising social buzz may signal near‑term upside for the biotech stock.